Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.

Phase 3

Withdrawn

Conditions: Pain

Interventions: Drug: IBUPROFEN + CAFFEINE
Drug: IBUPROFEN

First Posted Date: 2011-09-01

Last Posted Date: 2012-11-27

Lead Sponsor: Sanofi

Registration Number: NCT01426971

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Indolent Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: SAR245409

First Posted Date: 2011-08-05

Last Posted Date: 2016-04-01

Lead Sponsor: Sanofi

Target Recruit Count: 37

Registration Number: NCT01410513

Locations: 🇺🇸
Investigational Site Number 840006, Augusta, Georgia, United States
🇺🇸
Investigational Site Number 840002, Charleston, South Carolina, United States
🇺🇸
Investigational Site Number 840004, Aurora, Colorado, United States

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: SAR245409

First Posted Date: 2011-07-27

Last Posted Date: 2016-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 167

Registration Number: NCT01403636

Locations: 🇧🇪
Investigational Site Number 056003, Bruxelles, Belgium
🇺🇸
Investigational Site Number 840001, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 840002, Morgantown, West Virginia, United States

and more 27 locations

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon-β-1
Drug: teriflunomide
Biological: Influenza vaccine

First Posted Date: 2011-07-27

Last Posted Date: 2016-02-18

Lead Sponsor: Sanofi

Target Recruit Count: 128

Registration Number: NCT01403376

Locations: 🇦🇹
Investigational Site Number 040001, Wien, Austria
🇨🇦
Investigational Site Number 124002, London, Canada
🇨🇦
Investigational Site Number 124003, Greenfield Park, Canada

and more 11 locations

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: SAR245408

First Posted Date: 2011-07-13

Last Posted Date: 2014-12-03

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT01392924

Locations: 🇯🇵
Investigational Site Number 392002, Kobe-Shi, Japan
🇯🇵
Investigational Site Number 392001, Nagoya-Shi, Japan

Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

Conditions: Malignant Solid Tumors

Interventions: Drug: SAR125844

First Posted Date: 2011-07-12

Last Posted Date: 2016-04-13

Lead Sponsor: Sanofi

Target Recruit Count: 72

Registration Number: NCT01391533

Locations: 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇮🇹
Investigational Site Number 380001, Milano, Italy
🇫🇷
Investigational Site Number 250002, Dijon, France

and more 5 locations

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

Phase 2

Terminated

Conditions: Infection Prophylaxis

Interventions: Drug: placebo
Drug: SAR279356

First Posted Date: 2011-07-08

Last Posted Date: 2014-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 7

Registration Number: NCT01389700

Locations: 🇺🇸
Investigational Site Number 840010, Los Angeles, California, United States
🇺🇸
Investigational Site Number 840020, Stanford, California, United States
🇺🇸
Investigational Site Number 840001, Pikeville, Kentucky, United States

and more 3 locations

Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

Phase 3

Completed

Conditions: Malaria

Interventions: Drug: ARTESUNATE + AMODIAQUINE
Drug: Chloroquine

First Posted Date: 2011-06-22

Last Posted Date: 2013-07-18

Lead Sponsor: Sanofi

Target Recruit Count: 380

Registration Number: NCT01378286

Locations: 🇧🇷
Administrative office, Sao Paulo, Brazil

Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration

Phase 1

Terminated

Conditions: Stargardt's Disease

Interventions: Drug: SAR422459

First Posted Date: 2011-06-07

Last Posted Date: 2022-04-14

Lead Sponsor: Sanofi

Target Recruit Count: 27

Registration Number: NCT01367444

Locations: 🇺🇸
Investigational Site Number 840005, Iowa City, Iowa, United States
🇺🇸
Investigational Site Number 840001, Portland, Oregon, United States
🇫🇷
Investigational Site Number 250001, Paris, France

and more 2 locations

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: SAR245408 (XL147)
Drug: MSC1936369B

First Posted Date: 2011-05-20

Last Posted Date: 2016-04-01

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT01357330

Locations: 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇺🇸
Investigational Site Number 840002, Boston, Massachusetts, United States
🇺🇸
Investigational Site Number 840003, Nashville, Tennessee, United States

Home Terms & Conditions Privacy Policy